Serum TNF-α levels as a biomarker in some liver diseases of Egyptian patients | ||
| Journal of Medical and Life Science | ||
| Volume 5, Issue 1, March 2023, Pages 1-8 PDF (1.34 M) | ||
| Document Type: Original Article | ||
| DOI: 10.21608/jmals.2023.329303 | ||
| Authors | ||
| Ahmed Abdelhalim Yameny* 1; Sabah Farouk Alabd1; Magda Ahmed M. Mansor2 | ||
| 1Molecular Biology Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), University of Sadat City, Egypt | ||
| 2Department of Histology, Faculty of Medicine, Menoufia University, Egypt | ||
| Abstract | ||
| Background: Tumor necrosis factor alpha (TNF-α) is physiologically essential for a healthy immune response. Although TNF-α can help the immune system regulate, producing too much or inappropriate of it can be dangerous and can cause diseases. Patients and methods: this study was conducted on 90 patients with liver diseases and 25 healthy control G1, patients divided into 4 groups, (G2) 25 patients with HCV infection, (G3) 25 HCC+HCV infection, (G4) 25 patients with HBV infection, (G5) 15 patients with HCC + HBV. Results: There was a statistically significant difference between the five groups with p-value >0.001*, Compared to the control group the four groups HCV (G2), HCV+HCC (G3), HBV (G4), and HBV+HCC (G5) have the same statistically significant difference with the same (P1) p-value >0.001* which was significant. The serum TNF-α expression level of the HCV group (G2) was significantly elevated than HCV+HCC (G3) with a (P2) p-value of 0.010*significant. Still, the Serum TNF-α expression level of the HBV group (G4) was higher than HBV+HCC (G5) (61.05 ± 199.1, 14.36 ± 2.18 respectively) with (P7) p-value 0.960. Conclusion: Serum TNF-α can used as a biomarker to differentiate between healthy and infected patients with HCV or HBV and the development of HCC. | ||
| Keywords | ||
| Tumor necrosis factor alpha (TNF-α); HBV; HCV; HCC; Liver diseases | ||
|
Statistics Article View: 150 PDF Download: 314 |
||
